Status:
UNKNOWN
Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
Lead Sponsor:
Huashan Hospital
Conditions:
Acute Exacerbation Copd
Venous Thromboembolism
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
AECOPD increases the risk of VTE.VTE prevention is a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with VTE in Asian population is high and the mortality rate ...
Detailed Description
The acute exacerbation of COPD increases the risk of venous thromboembolism.VTE prevention is a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with VTE in Asian...
Eligibility Criteria
Inclusion
- AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization；Padua score \> 4；Age from 40-80y
Exclusion
- Patients whose admitting diagnosis was VTE；Patients whose duration of hospital stay was \<3 days or \>30 days ；Patients who received therapeutic doses of anticoagulants or thrombolytic therapy for any indication before hospitalization；an organic lesion that could bleed; severe liver or renal failure; confirmed or uncontrolled hypertension; a congenital or acquired coagulation disorder; a history of hypersensitivity or thrombocytopenia to heparins of any type；Patients who were contraindicated to anticoagulant therapy, venography, or angiography
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
438 Patients enrolled
Trial Details
Trial ID
NCT03277001
Start Date
October 1 2017
End Date
December 31 2019
Last Update
September 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan hospital,Fudan university
Shanghai, Shanghai Municipality, China, 200040